Home | Contact Us

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Recent News

Studies Further Demonstrate Clinical Utility & Cost-Effectiveness of bioTheranostics’ CancerTYPE ID® Molecular Test in Metastatic Cancer

bioTheranostics To Present Data on CancerTYPE ID® and Breast Cancer Index at 2013 ASCO Annual Meeting

bioTheranostics’ Prostate Cancer Index Predicts Risk for Prostate Cancer Recurrence

Prospective Study Shows that Therapy Guided by bioTheranostics’ CancerTYPE ID®  Molecular Test Improves Survival in Cancer of Unknown Primary Patients

Recent Publications

Medical Laboratory Observer:
Under Richard Ding’s direction, bioTheranostics focuses on biomarkers to aid in cancer treatment

Journal of Clinical Oncology:
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

ASCO Post:
Gene Profiling–guided Therapy May Improve Survival in Patients with Carcinoma of Unknown Primary

 

bioTheranostics develops and provides innovative oncology tests to support targeted disease management.

CancerTYPE ID® is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.
Learn More >

Breast Cancer IndexSM is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients diagnosed with estrogen receptor-positive, lymph node-negative breast cancer.
Learn More >

PRÉCIS® Precision Medicine by bioTheranostics
Includes biomarker profiles for non-small cell lung and colorectal cancer that detect clinically relevant tumor biomarkers.
Learn More >

© 2013 bioTheranostics. All rights reserved.
Client Services (877) 886-6739
Privacy Policy  |  Site Map  |  Speaker Bureau |  webmail